Literature DB >> 18333160

Surgical treatment of hepatocellular carcinoma.

Jacques Belghiti1, Reza Kianmanesh.   

Abstract

Surgery for hepatocellular carcinoma (HCC) includes partial liver resection (LR) and liver transplantation (LT). Although LT represents the most efficient treatment in patients with small HCC, <30% of patients are eligible for LT because of restrictive criteria (one nodule <5 cm or two to three nodules <3 cm without macroscopic vascular invasion), graft unavailability and the high cost of the procedure. For large HCC, LR remains the only potential curative treatment. LR is now safer, with a low rate of mortality. Selective preoperative morphological assessment, preoperative use of portal vein embolization for increasing future remnant liver volume and the improvement of surgical techniques such as the use of intermittent clamping and anterior approach are factors that improve the safety and tolerance of LR. In patients with small HCCs and a preserved liver function (Child-Pugh grade A), good long-term survival can be achieved after anatomical resection that removes the tumor(s) and its portal vein territory. These good results of LR for small HCC and the increasing duration of the waiting list for candidates of LT have renewed the place of LR as a bridge treatment before LT.

Entities:  

Year:  2005        PMID: 18333160      PMCID: PMC2023921          DOI: 10.1080/13651820410024067

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  88 in total

1.  Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations.

Authors:  J N Vauthey; A Chaoui; K A Do; M M Bilimoria; M J Fenstermacher; C Charnsangavej; M Hicks; G Alsfasser; G Lauwers; I F Hawkins; J Caridi
Journal:  Surgery       Date:  2000-05       Impact factor: 3.982

2.  Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma.

Authors:  Yun-Quan Luo; Yi Wang; Han Chen; Meng-Chao Wu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2002-11

3.  Repeat hepatectomy for recurrent hepatocellular carcinoma.

Authors:  N Nagasue; H Kohno; T Hayashi; M Uchida; T Ono; H Yukaya; A Yamanoi
Journal:  Br J Surg       Date:  1996-01       Impact factor: 6.939

4.  Future perspectives for hepatocellular carcinoma.

Authors:  W Y Lau
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

5.  Continuous versus intermittent portal triad clamping for liver resection: a controlled study.

Authors:  J Belghiti; R Noun; R Malafosse; P Jagot; A Sauvanet; F Pierangeli; J Marty; O Farges
Journal:  Ann Surg       Date:  1999-03       Impact factor: 12.969

6.  No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach.

Authors:  G Torzilli; M Makuuchi; K Inoue; T Takayama; Y Sakamoto; Y Sugawara; K Kubota; A Zucchi
Journal:  Arch Surg       Date:  1999-09

7.  Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

Authors:  J M Llovet; X Mas; J J Aponte; J Fuster; M Navasa; E Christensen; J Rodés; J Bruix
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

Review 8.  The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

9.  Evaluation of liver function for hepatic resection for hepatocellular carcinoma in the liver with damaged parenchyma.

Authors:  Hisao Wakabayashi; Ken Ishimura; Kunihiko Izuishi; Yukihiko Karasawa; Hajime Maeta
Journal:  J Surg Res       Date:  2004-02       Impact factor: 2.192

10.  Predictors and patterns of recurrence after resection of hepatocellular carcinoma.

Authors:  Charles Cha; Yuman Fong; William R Jarnagin; Leslie H Blumgart; Ronald P DeMatteo
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

View more
  44 in total

1.  Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database.

Authors:  Johannes Uhlig; Cortlandt M Sellers; Stacey M Stein; Hyun S Kim
Journal:  Eur Radiol       Date:  2018-12-17       Impact factor: 5.315

2.  Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Ming-chun Lai; Zhe Yang; Lin Zhou; Qian-qian Zhu; Hai-yang Xie; Feng Zhang; Li-ming Wu; Lei-ming Chen; Shu-sen Zheng
Journal:  Med Oncol       Date:  2011-06-16       Impact factor: 3.064

Review 3.  Surgical treatment of hepatocellular carcinoma: expert consensus statement.

Authors:  William Jarnagin; William C Chapman; Steven Curley; Michael D'Angelica; Charles Rosen; Elijah Dixon; David Nagorney
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

Review 4.  Resection for hepatocellular carcinoma.

Authors:  Hariharan Ramesh
Journal:  J Clin Exp Hepatol       Date:  2014-08-27

Review 5.  Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update.

Authors:  Marco Vivarelli; Roberto Montalti; Andrea Risaliti
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 6.  Current surgical treatment strategies for hepatocellular carcinoma in North America.

Authors:  Adeel S Khan; Kathryn J Fowler; William C Chapman
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

7.  Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma.

Authors:  Tan To Cheung; Sheung Tat Fan; Ferdinand S K Chu; Caroline R Jenkins; Kenneth S H Chok; Simon H Y Tsang; Wing Chiu Dai; Albert C Y Chan; See Ching Chan; Thomas C C Yau; Ronnie T P Poon; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-12-04       Impact factor: 3.647

Review 8.  Preoperative liver function assessments to estimate the prognosis and safety of liver resections.

Authors:  Toru Mizuguchi; Masaki Kawamoto; Makoto Meguro; Thomas T Hui; Koichi Hirata
Journal:  Surg Today       Date:  2013-03-09       Impact factor: 2.549

9.  FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

Authors:  Na Shang; Maribel Arteaga; Ali Zaidi; Jimmy Stauffer; Scott J Cotler; Nancy J Zeleznik-Le; Jiwang Zhang; Wei Qiu
Journal:  Hepatology       Date:  2014-11-25       Impact factor: 17.425

10.  Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.

Authors:  Sadakatsu Ikeda; Jordan S Lim; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.